Similarly, a trial of convalescent plasma for Ebola virus disease in Guinea revealed lower mortality in the plasma-treated group that failed to achieve significance, possibly because the sera used had insufficient antibody and a significant proportion of patients were treated late in the course of disease given that 17% died within 3 days of diagnosis ( 59 ).
← all excerpts
The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19.
1
—
—